https://orcid.org/0000-0003-2587-9181
References
- Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586–595.
- Gibson BES, Webb DKH, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366–376.
- Burnett AK, Russell NH, Hills RK, et al. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. J Clin Oncol. 2021;39(8):890–901.
- Getz KD, Alonzo TA, Sung L, et al. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2022;69(1):e29313.
- Hasegawa D, Tawa A, Tomizawa D, et al. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer. 2020;67(12):e28692.
- Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019;37(23):2072–2081.
- Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29(3):310–315.
- Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26–28.
- Wu D, Duan C, Chen L, et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep. 2017;7(1):1–10.
- Chen J, Glasser CL. Children new and emerging targeted therapies for pediatric acute myeloid leukemia (AML). Children. 2020;7(2):12.